Clostridioides difficile toxin B-binding proteins/endolysin combination LMN-201

An orally bioavailable combination agent composed of a whole, dried, non-viable biomass of spirulina (Arthrospira platensis) grown from four separate strains expressing three toxin-binding proteins targeting Clostridioides difficile toxin B (TcdB) and a phage-derived endolysin, with potential antibacterial activity. Upon oral administration of C. difficile TcdB-binding proteins/endolysin combination LMN-201, the C. difficile TcdB-binding proteins bind to distinct epitopes of the TcdB, thereby preventing the binding of the toxin to target host cells. TcdB is one of two exotoxins responsible for the symptoms of Clostridium difficile infections. In addition, the phage-derived endolysin degrades the cell wall of C. difficile, resulting in bacterial cell lysis. Altogether, this may prevent or treat C. difficile infection.